- Q1 2024 Verrica Pharmaceuticals Inc Earnings Call TranscriptMay 13, 2024$9.56 (+19.50%)Earnings
- Q4 2023 Verrica Pharmaceuticals Inc Earnings Call TranscriptFeb 29, 2024$5.27 (-7.87%)Earnings
- Q3 2023 Verrica Pharmaceuticals Inc Earnings Call TranscriptNov 09, 2023$3.21 (-9.83%)Earnings
- Verrica Pharmaceuticals Inc to Host KOL Event (Virtual) TranscriptOct 11, 2023
- Verrica Pharmaceuticals Inc to Discuss FDA Approval of YCANTH Call TranscriptJul 24, 2023
- Verrica Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2023
- Verrica Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) TranscriptApr 17, 2023
- Verrica Pharmaceuticals Inc at Cowen Health Care Conference TranscriptMar 06, 2023
- Verrica Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 14, 2022
- Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) TranscriptMay 19, 2021
- Verrica Pharmaceuticals Inc VIRTUAL PANEL: The Pursuit of Molluscum - Beetlejuice and Nobel Prizes TranscriptSep 22, 2020
Verrica Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
All right. Welcome back, everyone. I'm Dan Busby, the pharmaceuticals analyst at RBC Capital Markets, and I'm pleased to be joined by our next company, Verrica Pharmaceuticals, which we recently initiated coverage on. I'm joined this afternoon by Ted White, the company's President and Chief Executive Officer; Joe Bonaccorso, Chief Commercial Officer; Brian Davis, Chief Financial Officer; and Gary Goldenberg, Chief Medical Officer.
Ted, I'd like to start with you. It's an opportune time to have a conversation given your upcoming June 23 PDUFA for YCANTH in molluscum. Before we jump into Q&A, can you provide a little background on that product? Talk about the development and regulatory history for YCANTH that's brought you to where you are today?
Questions & Answers
Sure. Thanks, Dan. Well first, let me just start off by saying Verrica is a late-stage dermatology therapeutics company that's really focused on developing and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)